This review concluded that published data did not suggest an adverse effect of statins on cognition but the strength of available evidence was limited, particularly with regard to high-dose statins. The authors highlighted some limitations in their review. The authors' cautious conclusions reflect the evidence presented and their recommendation for further research seems appropriate.
Participant ages ranged from 11 to 89 years. Follow-up ranged from 0.3 to 69 years for cohort and case-control studies and 0.8 to 60 months for RCTs. Various assessment tools were used to test cognitive function.
Two reviewers independently screened studies for inclusion; one reviewer checked the FDA adverse event reporting databases.
Assessment of study quality
The authors assessed risk of bias for individual studies using the Cochrane risk of bias tool for RCTs and the NewcastleOttawa Scale for cohort and case-control studies. Evidence quality was assessed using the GRADE approach and graded as high if it included RCTs, low if it included observational studies and very low if it included only descriptive studies.
One reviewer assessed study quality which was then checked by a second reviewer.
Data extraction
Two reviewers independently extracted data to calculate relative risks and related 95% confidence intervals. Incidence of dementia, Alzheimer's disease or mild cognitive impairment were extracted as well as the cognitive performance scores (categories included global cognitive performance, frontal-executive function and working memory, declarative memory, procedural memory, attention, processing speed, visuoperception and motor speed).
Methods of synthesis
Pooled adjusted (if available) relative risks and 95% confidence intervals were calculated using a random-effects model. Where RCTs or observational studies precluded quantitative synthesis, results from individual studies were summarised qualitatively. Sensitivity analysis was performed for studies with lower and higher risk of bias. Adverse event reporting rates were calculated by dividing the number of cognitive-related adverse event cases for statins with the total number of cases of adverse events or the total number of prescriptions dispensed. Adverse event reporting rates were calculated for losartan and clopidogrel.
Results of the review
Fifty-seven studies were included in the review and 27 of these -three RCTs, 16 cohort, four case-control and four cross-sectional studies -were included in the meta-analysis. Four RCTs, four cohort studies and two case-control studies met the criteria for the lowest risk of bias. In most RCTs, insufficient information was available to judge
